

Summary of Lothian Joint Formulary Amendments

The purpose of this summary is to detail the main changes to the LJF sections and provide additional information on the reasons for some of the changes. The website chapters should be referred to for full details. The month indicates when Formulary Committee approved the changes.

September 2020

Chapter 1 Gastrointestinal - Adults

1.5.1 (c) Maintenance of remission of ulcerative colitis

- VSL#3 has been removed from the formulary. The Advisory Committee on Borderline Substances (ACBS) advised that evidence on its clinical effectiveness was not sufficiently demonstrated. It is no longer included in the Drug Tariff and can no longer be prescribed under (ACBS) criteria.

1.6 Laxatives (d) other drugs used in constipation

- naldemedine is indicated for the treatment of opioid-induced constipation (OIC) in adult patients who have previously been treated with a laxative. It should be initiated on specialist advice only.
- lactulose is included for specialist initiation in Women's Services for the treatment of constipation in postpartum patients following caesarean section and for patients with third- or fourth-degree tears.

Chapter 4 CNS - Adults

4.4 (b) Attention deficit hyperactivity disorder

- The preferred brand of methylphenidate modified-release tablets 18mg, 27mg, 36mg, 54mg is Xaggitin XL®.

4.7 pain with a neuropathic component

- The amitriptyline dose is updated in line with the BNF.

4.9.2 Antimuscarinic drugs used in Parkinsonism

- orphenadrine has been deleted and procyclidine added in line with longstanding local practice.

4.10 Drugs used in substance dependence

- naloxone nasal spray 1.8mg (Nyxoid®) has been added for individuals in secure environments, e.g. prisons, for whom an intramuscular preparation is not desirable or tolerated.

Chapter 6 Endocrine - Adults

6.1.2 (iii) Glucagon-like peptide (GLP-1) agonist

- semaglutide tablets added following an SMC abbreviated submission.

6.6 Drugs affecting bone metabolism

- Calcichew D3® caplets and Calcichew D3 Forte® have been replaced with Accrete D3® One a Day or Accrete D3® (*formulary amendment request forms July 2020 for Accrete D3® (calcium carbonate / colecalciferol) film-coated tablets & Accrete D3® (calcium carbonate / colecalciferol) chewable tablets*).

Chapter 9 Nutrition and Blood - Adults

9.6.4 Calcium and Vitamin D supplements

- Calcichew D3® caplets and Calcichew D3 Forte® replaced with Accrete D3® One a Day or Accrete D3® (*Formulary amendment request forms July 2020 for Accrete D3® (calcium carbonate / colecalciferol) film-coated tablets & Accrete D3® (calcium carbonate / colecalciferol) chewable tablets*).

Chapter 13 Skin - Adults

13.2.1 Emollients

- QV intensive ointment® added as second choice ointment base emollient.
- QV 5% skin lotion® added as second choice cream base emollient.

13.2.1.1 Emollient bath/shower additives

- Oilatum® emollient bath additive, Oilatum® shower gel fragrance free and Oilatum® plus bath additive removed. Dermol® 200 shower emollient, QV Gentle wash® and Hydromol® Bath and Shower emollient added.

13.5.1 Preparations for atopic eczema

- The prescribing notes for topical calcineurin inhibitors and oral immunosuppressants have been updated.

13.8.1 Sunscreens

- The prescribing notes on sunscreens have been updated with Advisory Committee on Borderline Substances (ACBS) criteria.

Chapter 2 Cardiovascular – Child

2.1.1 Cardiac glycosides

- digoxin dose updated in line with BNFC.

Chapter 4 CNS - Child

4.1.1 Hypnotics

- melatonin Pharma Nord 3mg film coated tablets are now melatonin Pharma Nord Syncrodin® 3mg film coated tablets.

4.12 Attention deficit hyperactivity disorder

- The preferred brand of methylphenidate modified-release tablets 18mg, 27mg, 36mg, 54mg is Xaggitin XL®.

Chapter 6 Endocrine - Child

6.1.2 (b) Sulphonylureas

- glibenclamide removed as a choice, following discontinuation.

Chapter 9 Nutrition and Blood - Child

9.6.4 Calcium and vitamin D supplements

- Calcichew® D3 caplets removed as the product is now discontinued.

Chapter 13 Skin - Child

13.2.1 Emollients

- QV intensive ointment® added as second choice ointment base emollient.
- QV 5% skin lotion® added as second choice cream base emollient.

13.2.1.1 Emollient bath/shower additives

- Oilatum® emollient bath additive, Oilatum® shower gel fragrance free and Oilatum® plus bath additive removed. Dermol® 200 shower emollient, QV Gentle wash® and Hydromol® Bath and Shower emollient added.

13.8.1 Sunscreens

- The prescribing notes on sunscreens have been updated with Advisory Committee on Borderline Substances (ACBS) criteria.

Wound Formulary

13.3.1 Wound management products (a) alginate dressings

- Algosteril discontinued, Kaltostat added.

Minor Ailments Formulary

The Minor Ailments Service (MAS) is now replaced by the new NHS Pharmacy First Scotland service. The new guide, titled 'East Region Formulary - Pharmacy First supporting minor ailments' provides supporting information, including prescribing notes for items available on the Pharmacy First service. The guide is approved for use in Lothian and is currently available as a PDF document accessed from the formulary website.

Appendix 1 - Requesting formulary amendments

Appendix 1 has been updated with further guidance on how to request changes to the formulary content with useful signposts to additional information